戻る
Vir Biotechnology Inc (VIR)価格
VIR 株価推移チャート
VIR 収入
Vir Biotechnology Inc
$6.06
-2.25%
$-0.14
終値： Jan 16, 16:00:00 GMT-5
$6.01
-0.82%
$-0.04
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$6.2
始値
$6.22
当日レンジ
$6.01 - $6.25
52週レンジ
$4.15 - $11.39
取引高
1.6M
平均取引高
1.7M
1株当たり利益(TTM)
-3.62
配当利回り
--
時価総額
$836.1M
VIRとは何ですか？
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 408 full-time employees. The company went IPO on 2019-10-11. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. The company also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. The company also has rights to the PRO-XTEN masking platform for oncology and infectious disease.